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Introduction
Complaints of problems with memory and thinking are 
common in breast cancer survivors [1]. Initially, patients 
and researchers focused on chemotherapy as the possible 
cause of this cognitive dysfunction [2-7]. More recently, 
research has examined the potential role of adjuvant 
endocrine therapies.
Most postmenopausal women with early-stage breast 
cancer have estrogen receptor-positive disease and 
require at least 5 years of adjuvant endocrine therapy as 
part of their treatment [8]. Th   e endocrine therapies most 
commonly used for postmenopausal breast cancer are 
tamoxifen and aromatase inhibitors, such as anastrozole, 
exemestane, and letrozole. Tamoxifen binds to estrogen 
receptors and has mixed agonist and antagonist 
properties, depending on the target tissue [9]. Tamoxifen 
does not alter circulating estrogen levels in postmeno-
pausal women. Conversely, the aromatase inhibitors 
reduce circulating estrogen to very low levels by inhibit-
ing the conversion of adrenally secreted androstenedione 
to estradiol in adipose tissue. Large clinical trials have 
demonstrated that aromatase inhibitors are superior to 
tamoxifen in the treatment of early-stage, postmeno-
pausal, hormone receptor-positive breast cancer [10]. It 
is now recommended that an aromatase inhibitor be 
considered for all postmenopausal women with early-
stage, hormone receptor-positive breast cancer and that 
potential side eﬀ   ects be carefully considered when 
deciding on adjuvant endocrine therapy [10]. Some side 
eﬀ  ects of aromatase inhibitors are well characterized, but 
others, such as their potential eﬀ  ect on cognitive func-
tion, are not well understood.
Preclinical data on the role of estrogen and 
cognitive function
Th  ere is substantial biological evidence supporting the 
importance of estrogen in cognitive function [11]. 
Estrogen receptors are found in many areas of the brain 
considered important in cognition, including the hippo-
campus, prefrontal cortex, and amygdala [12]. Estrogen 
may enhance cognitive function by means of several 
diﬀ   erent mechanisms (Table 1). Th  e cholinergic and 
glutamate neurotransmitter systems, both important for 
regulation of memory and learning, are enhanced by 
estrogen [13-15]. Estrogen enhances neuronal plasticity 
[16,17] and has a favorable eﬀ  ect on serum lipid proﬁ  les 
by reducing low-density lipoproteins and increasing 
high-density lipoproteins, which may slow progression of 
cerebral atherosclerosis and thus prevent cognitive 
decline [18]. Estrogen also modulates the expression of 
the apolipoprotein E gene [19], one variant of which is 
associated with an increased risk for Alzheimer’s disease 
and preclinical cognitive decline [20]. However, the eﬀ  ect 
of estrogen on cognitive function is complex and may 
depend on underlying neurological health at the time of 
estrogen exposure. It has been hypothesized that if 
neurological processes are healthy at the time of estrogen 
exposure, then estrogen is beneﬁ  cial, but that estrogen 
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health may exacerbate cognitive dysfunction [21].
It is not clear whether tamoxifen acts as an agonist or 
antagonist in the brain [22,23]. Aromatase is expressed in 
many regions of the brain, although little is known about 
its role and implications for cognitive function. Th  e  very 
low levels of circulating estrogen which occur with the 
use of aromatase inhibitors in postmenopausal women 
might be expected to result in a deterioration in cognitive 
function. Conversely, recent data suggest that letrozole 
administration may enhance cognition in both male and 
female rats [24,25].
Clinical studies of aromatase inhibitors and 
cognitive function
Despite the widespread use of aromatase inhibitors in the 
treatment of breast cancer, only a handful of studies have 
evaluated the impact of aromatase inhibitors on cognitive 
function [26-33], and the results are conﬂ  icting (Table 2). 
Details on study design, timing of cognitive function 
measures, numbers of patients at baseline and last 
follow-up, and post hoc power are given in Table 2.
Data from randomized comparisons
Th  e most robust data on this issue come from three 
studies undertaken as substudies within large random-
ized controlled trials [28,29,32,33]. One compared 
cognitive eﬀ  ects of an aromatase inhibitor with those of 
placebo [28]. Th  e other two compared the cognitive 
function of women randomly assigned to receive tamoxi-
fen with those randomly assigned to receive an aromatase 
inhibitor [29,32]. A fourth substudy, though performed 
within a randomized controlled trial, is considered in a 
subsequent section, rather than here, because the 
comparison performed in that substudy was not between 
data from randomly assigned subjects [26].
IBIS II and TEAM studies
In a substudy of the double-blind International Breast 
Intervention Study II (IBIS II) [28], the cognitive function 
of postmenopausal women who had an increased risk for 
breast cancer and who were randomly assigned to 
anastrozole was compared with that of those randomly 
assigned to placebo. Cognitive function was assessed 
prior to random assignment (n = 227), at 6 months (n = 207, 
91%), and at 2 years (n = 151, 67%). Th   e functional areas 
of verbal and visual memory, working memory, process-
ing speed, and executive function were assessed. Th  ere 
was no signiﬁ  cant diﬀ  erence between the anastrozole and 
placebo groups on any cognitive tasks at any of the time 
points. Post hoc power calculations (results presented in 
Table 2) show that each comparison in this study had 
reasonable power to detect a moderate diﬀ  erence  in 
cognitive function between those treated with anastro-
zole versus placebo.
Th  e open-label Tamoxifen and Exemestane Adjuvant 
Multinational (TEAM) study randomly assigned post-
meno  pausal women with early-stage breast cancer to 
receive adjuvant exemestane for 5 years or tamoxifen for 
2.5 to 3 years followed by exemestane for 2 to 2.5 years 
[29]. Th  e cognitive domains of verbal memory, visual 
memory, processing speed, executive function, manual 
motor speed, verbal ﬂ   uency, and reaction speed were 
assessed prior to commencement of adjuvant endocrine 
therapy and after 1 year on therapy in a subgroup of 179 
women (and a non-randomly assigned group of 120 
untreated healthy controls who were similarly aged 
friends or relatives of trial participants). Th  e cognitive 
function of those randomly assigned to exemestane was 
compared with that of those randomly assigned to 
tamoxifen. Tamoxifen-treated patients had slower 
information-processing speed in comparison with those 
treated with exemestane. Th   is study had adequate power 
to detect moderate-sized eﬀ  ects on cognitive function 
(Table 2). Cognitive function was also compared between 
non-randomly assigned groups (that is, those randomly 
assigned to tamoxifen and healthy controls and those 
randomly assigned to exemestane and healthy controls). 
Th  ose results are discussed in the relevant section of 
‘Data from non-randomized comparisons’ below.
Th   e IBIS II and TEAM studies provide good evidence 
that there is no moderate or large adverse eﬀ  ect  of 
aromatase inhibitors on cognitive func  tion when 
compared with placebo or tamoxifen. However, smaller 
eﬀ  ects on cognitive function cannot be excluded. Conﬁ  r-
matory controlled studies would provide additional 
reassurance but are unlikely. It is also important to note 
that the data from these two studies do not provide 
information about the cognitive eﬀ  ects of more than 2 
years of aromatase inhibitor therapy. In neither the IBIS 
II nor the TEAM study did the patients receive chemo-
therapy, so the results are not confounded by potential 
cognitive alterations induced by prior chemotherapy.
BIG 1-98
Th   e double-blind Breast International Group 1-98 
(BIG  1-98) study randomly assigned postmenopausal 
Table 1. Mechanisms whereby estrogen may enhance 
cognitive function
•  Enhancement of cholinergic and glutamate neurotransmitter systems [13-
15]
•  Enhancement of neuronal survival, diff  erentiation, regeneration, and 
plasticity [16,17]
• Favorable  eff  ect on serum lipid profi  les [18]
•  Modulation of expression of apolipoprotein E [19]
Note: the relationship between estrogen and cognitive function is complex and 
likely non-linear.
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receive one of the following adjuvant endocrine therapy 
options: (a)  tamoxifen for 5  years, (b) letrozole for 
5 years, (c) tamoxifen for 2 years followed by letrozole for 
3 years, or (d) letrozole for 2 years followed by tamoxifen 
for 3 years. Patients were stratiﬁ  ed according to whether 
or not they had received prior chemotherapy. In a small 
subset of 120 patients, a cognitive function substudy 
examined the diﬀ  erences in cognitive function associated 
with each endocrine treatment [32]. A brief computerized 
battery of tests measuring psychomotor speed, visual 
attention, working memory, visual learning and memory, 
and verbal learning and memory (CogState Ltd., Mel-
bourne, Australia) [34] was administered after approxi-
mately 5 years on therapy and again approxi  mately 1 year 
after ceasing therapy. During the ﬁ  fth year on adjuvant 
Table 2. Clinical studies of aromatase inhibitors and cognitive function
Powera
Study
Study 
design
Timing of 
measures
Number 
at 
baseline
Number 
at last 
follow-up
Treatment 
comparison ES = 0.50 ES = 0.35 Conclusions
IBIS II [28] RCT Pre-Rx, at 6 
months on Rx, 
and at 2 years 
on Rx
227 151 Anastrozole
Placebo
94% (6-month 
analysis), 
87% (2-year 
analysis)
71% (6-month 
analysis), 
58% (2-year 
analysis)
No statistically signifi  cant 
diff  erence in cognitive 
function between arms was 
observed.
TEAM [29] RCT and 
control 
group
Pre-Rx and at 1 
year on Rx
179 
+ 120 
healthy 
controls
179 
+ 120
Exemestane
Tamoxifen ( 
exemestane)
93% (tamoxifen 
compared with 
exemestane), 
93% (tamoxifen 
compared with 
control), 
96% (exemestane 
compared with 
control)
67% (tamoxifen 
compared with 
exemestane), 
68/% (tamoxifen 
compared with 
control), 
73% (exemestane 
compared with 
control)
No statistically signifi  cant 
eff  ect of exemestane on 
cognition was observed; 
tamoxifen was associated 
with worse verbal memory, 
executive function, and 
information-processing speed.
BIG 1-98 
[32,33]
RCT  At 5 years on 
Rx and 1 year 
after ceasing Rx
120 100 Tamoxifen or 
letrozole  
tamoxifen
Letrozole or 
tamoxifen  
letrozole
78% 48% Overall cognitive function was 
signifi  cantly better in patients 
taking letrozole rather than 
tamoxifen at year 5.
Signifi  cant improvement in 
cognition after completion 
of endocrine therapy was 
observed.
ATAC [26] Cross-
sectional
At 1 to 5 years 
on Rx (mean of 
3 years)
94 
+ 35 
healthy 
controls
N/A Anastrozole 
or tamoxifen 
(combined)
Untreated
71% 42% Endocrine therapy users had 
worse verbal memory and 
processing speed compared 
with untreated controls.
Bender, et 
al. [27]
Cross-
sectional, 
non-
randomized
At >3 months 
on Rx
31 N/A Anastrozole
Tamoxifen
28% 16% Poorer verbal and visual 
learning in patients taking 
anastrozole compared with 
patients taking tamoxifen was 
observed.
Collins, et 
al. [31]
Non-
randomized
Around start of 
Rx and at 5 to 6 
months on Rx
45 
+ 28 
healthy 
controls
‘Attrition 
<10% in 
all groups’
Anastrozole
Tamoxifen
48% (tamoxifen), 
33% (anastrozole)
27% (tamoxifen), 
19% (anastrazole)
No signifi  cant diff  erence 
between treatments, relative 
to healthy controls, was 
observed. 
Hermelink, 
et al. [30]
Non-
randomized
Before start of 
CT, before fi  nal 
cycle of CT, and 
at 1 year (after 
baseline)
101 92 Anastrozole or 
letrozole
Tamoxifen
61% 35% No statistically signifi  cant 
diff  erence between tamoxifen 
and aromatase inhibitor on 
any cognitive domain was 
observed.
aThe power calculations are for comparing two groups, with the numbers of patients as given in each paper, for eff  ect sizes (ESs) of both 0.50 (medium) and 0.35 
(small to medium). Two-sided tests at the alpha = 0.05 level are assumed. The calculations are necessarily indicative only and do not closely incorporate all the design 
features of the studies which might aff  ect power (including data quality and completeness) or adjust for multiple comparisons. ATAC, Anastrozole, Tamoxifen Alone 
or Combined; BIG 1-98, Breast International Group 1-98; CT, chemotherapy; IBIS II, International Breast Intervention Study II; N/A, not applicable; RCT, randomized 
controlled trial; Rx, endocrine treatment; TEAM, Tamoxifen and Exemestane Adjuvant Multinational.
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C) had better overall cognitive function in comparison 
with those taking tamoxifen (arms A and D). Th  e  analysis 
comparing the monotherapy arms in this study was 
underpowered and showed no statistically signiﬁ  cant 
diﬀ  erence between the cognitive function of women who 
had taken tamoxifen for 5 years and those who had take 
letrozole for 5 years.
A novel aspect of the BIG 1-98 cognitive function 
substudy was that it also assessed cognition approxi-
mately 1 year after patients had completed their adjuvant 
endocrine therapy [33]. Th   e substudy showed signiﬁ  cant 
improvement in cognition after cessation of therapy. Th  e 
ﬁ   nding was consistent across all cognitive tasks and 
consistent in women taking either tamoxifen or letrozole 
at the 5-year time point. Th  e observed eﬀ  ect size was 
moderate for the change in overall cognition. In this 
study, cognitive function was not assessed prior to the 
start of endocrine therapy, so it is not clear how cognition 
1 year after cessation of therapy might have compared 
with baseline cognitive function prior to commencement 
of adjuvant endocrine therapy. Nevertheless, this study 
suggests that any eﬀ  ect that adjuvant endocrine therapy 
might have on cognition in postmenopausal women is at 
least partly reversible with cessation of endocrine 
therapy.
Data from non-randomized comparisons
ATAC
In a pilot substudy of the randomized trial of Anastrozole, 
Tamoxifen Alone or Combined (ATAC) [26], the 
cognitive function of 94 breast cancer patients taking 
adjuvant tamoxifen or anastrozole (analyzed together) 
was compared with that of a convenience sample of 35 
healthy untreated controls. None of the patients had had 
prior chemotherapy. Standard neuropsychological tests, 
which consisted of measures of processing speed, 
working memory, attention, visual memory, and verbal 
memory, were used. Women were tested after 12 to 
60  months of adjuvant endocrine therapy (mean of 
36  months). Th   ose receiving adjuvant endocrine therapy 
performed less well on tests of verbal memory and 
processing speed compared with untreated controls. A 
comparison of the cognitive function of women taking 
anastrozole with that of women taking tamoxifen was not 
performed as the sample size was considered too small; 
thus, this study does not provide speciﬁ  c information on 
the impact of aromatase inhibitors on cognitive function.
TEAM
Th  e TEAM study has been described above [29]. In 
addition to conducting a comparison between the 
randomly assigned groups in this study, the authors 
compared the cognitive function of healthy controls with 
that of those randomly assigned to tamoxifen or 
exemestane. After 1 year of use, exemestane was not 
statistically signiﬁ  cantly associated with lower cognitive 
function in comparison with healthy controls, whereas 1 
year of tamoxifen treatment was associated with worse 
performance in terms of verbal memory and executive 
function. Th   e observed eﬀ  ect sizes were moderate for all 
aﬀ  ected cognitive domains.
Th  ree other non-randomized studies have examined 
the inﬂ  uence on cognitive function of tamoxifen com-
pared with aromatase inhibitors [27,30,31]. Two studies 
found no statistically signiﬁ  cant  diﬀ   erence in overall 
cognitive function between patients taking tamoxifen 
versus aromatase inhibitors [30,31], but these studies 
were small and underpowered (Table 2). Th  e third, a 
cross-sectional study of a small convenience sample of 31 
postmenopausal women, suggested that learning and 
memory were worse in breast cancer patients treated for 
at least 3 months with anastrozole (n = 15) compared 
with tamoxifen (n = 16) [27]. However, the women who 
received tamoxifen in that study had been taking the 
endocrine therapy for signiﬁ   cantly longer (mean of 
23.8 months versus 14.3 months) and were signiﬁ  cantly 
younger (mean of 48.2 years versus 57.4 years) than those 
who received anastrozole, and this may have confounded 
the results. Also, the cross-sectional design, with no pre-
treatment measures, makes it impossible to determine 
whether the results represent a change from pre-
treatment performance.
Interpretation and future research directions
To date, the hypothesis that aromatase inhibitors might 
have an adverse impact on cognitive function and might 
be worse than tamoxifen in that regard (because of lower 
circulating estrogen levels during treatment with 
aromatase inhibitors) has not been conﬁ   rmed by the 
available data. However, there are a number of limitations 
of the existing studies and further robustly designed 
research is required.
Limitations of existing studies
Four of the studies reviewed used a convenience/observa-
tional sample design [26,27,30,31]. Th  is is a weakness 
because any observed association between cognitive 
function and type of endocrine therapy used is not 
necessarily causal, because of the possibility of underlying 
confounding. Substudies within randomized controlled 
trials are a potentially more valid approach because they 
are less susceptible to bias.
All studies had relatively small sample sizes and thus 
limited power to detect small eﬀ   ects on cognitive 
function, although two [28,29] were adequately powered 
to detect moderate eﬀ  ects (Table 2). Th   e nature of studies 
looking for evidence of cognitive impairment is such that 
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which cognitive impairment may be expressed (cognitive 
domains), need to be examined. Th   is implies that studies 
need to be designed and their results interpreted 
appropriately in order to avoid excessive risk of false-
positive errors. Th  is usually requires that a priori 
summary measures be employed (as in the BIG 1-98 
study) or that analytic methods, such as those of Hoch-
berg, Holm, or Bonferroni, be used. Such requirements 
may have implications for sample size in these studies.
Only one of the published studies provides data on the 
eﬀ   ect of aromatase inhibitors on cognition over the 
longer term [32,33]. Th   is is an important point given that 
most women receive at least 5 years of adjuvant 
endocrine therapy.
Future research
It is disappointing that, despite random assignment of 
tens of thousands of women in adjuvant and preventive 
endocrine therapy trials, there are still inadequate data 
regarding the cognitive eﬀ  ects of aromatase inhibitors. 
Consideration should be given to incorporating measures 
of cognitive function into the main protocol of future 
studies in the same way that quality-of-life measures 
often are. Th  is would avoid the need for separate sub-
studies, recruitment to which can be hampered by the 
need for separate funding, protocols, and ethics approval. 
Of course, assessing cognitive function in multi-
institutional, often multi-national, studies is potentially 
challenging. Th   e use of relatively brief, validated 
computerized tools, such as that used in the BIG 1-98 
study (CogState Ltd.) [34], rather than lengthy ‘paper and 
pencil’ standard neuropsychological tests, should make 
this more feasible. Future research might also employ 
translational approaches using functional brain imaging 
or may include study designs other than clinical trials 
(such as population-based studies using SEER 
[Surveillance, Epidemiology and End Results] data linked 
to Medicare claims, although such designs also have 
limitations [35]) or both. Studies of cognitive function in 
larger samples of patients would enable important sub-
group analyses, driven by biological hypotheses, to be 
undertaken.
Th  e role of estrogen in cognitive function is clearly 
important but complex. Th   e relationship between 
amount of circulating estrogen and cognitive function 
may not be linear. It has been suggested that estrogen 
may have either protective or harmful eﬀ  ects on the brain 
depending on age, type of menopause (natural versus 
surgical), or stage of menopause [36]. Several studies 
have suggested that surgical oophorectomy in premeno-
pausal women adversely impacts cognitive function, 
particularly verbal memory, and that the eﬀ  ect can be 
ameliorated by the use of hormone replacement therapy 
[37-39]. A recent study suggested that premenopausal 
oophorectomy is a risk factor for cognitive impairment 
and dementia later in life [40]. However, adverse eﬀ  ects 
of estrogen on cognitive function have also been 
suggested. In the Women’s Health Initiative Study, which 
randomly assigned postmenopausal women to estrogen 
replacement therapy or placebo, estrogen increased the 
risk of dementia in women older than 65 years [41,42]. 
Th   is suggests that, while estrogens may be protective of 
cognition around the time of menopause, they may have 
detrimental eﬀ   ects on older women. Th  e question of 
whether aromatase inhibitors have a more adverse eﬀ  ect 
on the cognitive function of younger postmenopausal 
women, who may not have already adapted to relative 
hypo-estrogenism, in comparison with older postmeno-
pausal women requires further research. Th  is will be 
especially important if ovarian ablation combined with 
aromatase inhibitors becomes a standard of care for 
premenopausal women with early-stage breast cancer 
[43]. Similarly, it would be of interest to know whether 
women who use estrogen replacement therapy prior to 
their breast cancer diagnosis might be more likely than 
those who do not to develop cognitive dysfunction when 
taking aromatase inhibitors.
Overweight women generally have more aromatase 
enzyme availability. In a study of premenopausal patients 
treated with a gonadotropin-releasing hormone (GnRH) 
agonist and anastrozole, those who were overweight had 
worse disease-free survival compared with patients of 
normal weight [44]. It has been hypothesized (but not 
proven) that, in overweight women, the standard dose of 
aromatase inhibitor may not be suﬃ   cient to adequately 
lower estrogen levels. Th  us, it would be of interest to 
examine whether aromatase inhibitors might have diﬀ  er-
ent eﬀ  ects on cognitive dysfunction in overweight and 
obese women compared with women of normal weight. 
Another question of considerable interest is whether 
women who get worse menopausal side eﬀ  ects, such as 
hot ﬂ  ushes, from aromatase inhibi  tors might be more 
likely to develop cognitive problems.
Whether diﬀ   erent aromatase inhibitors might have 
diﬀ  erent eﬀ  ects on cognition is an important question 
but is currently unanswered on the basis of the available 
data. In contrast to the non-steroidal aromatase inhibi-
tors anastrozole and letrozole, the steroidal aromatase 
inhibitor exemestane has androgenic properties that 
might confer an advantage for cognitive functioning 
[45,46]. Future research diﬀ   erentiating any possible 
cogni tive  eﬀ   ect of the diﬀ   erent available aromatase 
inhibi  tors would be of considerable interest.
Most studies to date have not demonstrated a signiﬁ  -
cant association between objective cognitive impairment 
and patients’ self-report of their cognitive function, but 
several studies have found signiﬁ  cant  correlations 
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and/or anxiety [26,28,47,48]. Th  us, subjective cognitive 
complaints may be an indicator of an underlying mood 
disorder. Patients who report memory problems while 
taking aromatase inhibitors should be evaluated for a 
potential mood disorder, as these can be eﬀ  ectively 
treated.
Conclusions
During discussions of cognitive dysfunction as a possible 
side eﬀ  ect of adjuvant endocrine therapy, women should 
be told of the limitations of the current evidence in this 
area. However, with that caveat, it is reasonable to tell 
postmenopausal women that there is currently no clear 
evidence that use of an aromatase inhibitor to treat their 
breast cancer will result in a deterioration in their 
cognitive function. Th   ey can also be informed that, given 
the available evidence, the eﬀ   ect of an aromatase 
inhibitor on cognitive function does not appear to be 
worse than that of the alternative agent, tamoxifen.
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